Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease

European Urology

Volumn 65, Issue 1, 2014, Pages 177-185

  Nanda, Akash ^a   Chen, Ming Hui ^b   Moran, Brian J ^c   Braccioforte, Michelle H ^c   Dosoretz, Daniel ^d   Salenius, Sharon ^d   Katin, Michael ^d   Ross, Rudi ^d   D'Amico, Anthony V ^e  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c Prostate Cancer Foundation of Chicago   (United States)

^d 21ST CENTURY ONCOLOGY   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Brachytherapy; Coronary artery disease; Diabetes mellitus; Hypercholesterolemia; Hypertension; Neoadjuvant hormonal therapy; Prostate cancer; Risk factors

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CARDIOVASCULAR RISK; CAUSE OF DEATH; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HEART INFARCTION; HORMONAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NEOADJUVANT HORMONE THERAPY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK; RISK FACTOR; ADJUVANT THERAPY; COMPLICATION; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK ASSESSMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; CORONARY ARTERY DISEASE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84888830663     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.08.070     Document Type: Article

References (30)

1. A.V. D'Amico, M.H. Chen, A.A. Renshaw, M. Loffredo, and P.W. Kantoff Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 299 2008 289 295
2. V. Pagliarulo, S. Bracarda, and M.A. Eisenberger Contemporary role of androgen deprivation therapy for prostate cancer Eur Urol 61 2012 11 25
3. A. Heidenreich, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
4. A. Nanda, M.H. Chen, M.H. Braccioforte, B.J. Moran, and A.V. D'Amico Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction JAMA 302 2009 866 873
5. M. Braga-Basaria, A.S. Dobs, and D.C. Muller Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy J Clin Oncol 24 2006 3979 3983
6. N.L. Keating, A.J. O'Malley, S.J. Freedland, and M.R. Smith Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol 64 2013 159 166
7. J.C. Hu, S.B. Williams, A.J. O'Malley, M.R. Smith, P.L. Nguyen, and N.L. Keating Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism Eur Urol 61 2012 1119 1128
8. L. Azoulay, H. Yin, S. Benayoun, C. Renoux, J.F. Boivin, and S. Suissa Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer Eur Urol 60 2011 1244 1250
9. J.W. Denham, A. Steigler, and D.S. Lamb Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial Lancet Oncol 6 2005 841 850
10. M.V. Pilepich, K. Winter, and M.J. John Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
11. A.V. D'Amico, J. Manola, M. Loffredo, A.A. Renshaw, A. DellaCroce, and P.W. Kantoff 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 292 2004 821 827
12. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 2002 103 106
13. F.L. Greene, D.L. Page, and I.D. Fleming AJCC cancer staging manual ed. 6. 2002 Lippincott Philadelphia, PA
14. A.M. Dosoretz, M.H. Chen, and S.A. Salenius Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy Cancer 116 2010 837 842
15. C.D. Newgard, J.R. Hedges, M. Arthur, and R.J. Mullins Advanced statistics: the propensity score - a method for estimating treatment effect in observational research Acad Emerg Med 11 2004 953 961
16. J.P. Klein, and M.L. Moeschberger Survival analysis ed. 2. 2003 Springer-Verlag New York, NY
17. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
18. L.A. Cupples, D.R. Gagnon, R. Ramaswamy, and R.B. D'Agostino Age-adjusted survival curves with application in the Framingham Study Stat Med 14 1995 1731 1744
19. N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1966 163 170
20. J.P. Shaffer Multiple hypothesis-testing Ann Rev Psych 46 1995 571 584
21. P. Greenland, M.D. Knoll, and J. Stamler Major risk factors as antecedents of fatal and nonfatal coronary heart disease events JAMA 290 2003 891 897
22. U.N. Khot, M.B. Khot, and C.T. Bajzer Prevalence of conventional risk factors in patients with coronary heart disease JAMA 290 2003 898 904
23. G.N. Levine, A.V. D'Amico, and P. Berger Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology Circulation 121 2010 833 840
24. B.C. Tanis, M.A. van den Bosch, and J.M. Kemmeren Oral contraceptives and the risk of myocardial infarction N Engl J Med 345 2001 1787 1793
25. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1997;349:1202-9.
26. V. Beral, C. Hermon, C. Kay, P. Hannaford, S. Darby, and G. Reeves Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners' oral contraception study BMJ 318 1999 96 100
27. L. Rosenberg, J.R. Palmer, R.S. Rao, and S. Shapiro Low-dose oral contraceptive use and the risk of myocardial infarction Arch Intern Med 161 2001 1065 1070
28. L. Wei, T.M. MacDonald, and B.R. Walker Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease Ann Intern Med 141 2004 764 770
29. M. Petri, C. Lakatta, L. Magder, and D. Goldman Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis Am J Med 96 1994 254 259
30. C.U. Jones, D. Hunt, and D.G. McGowan Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2011 107 118